Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 8/20 | 0.57 |
| ▸ | CTSG | P08311 | 5/20 | 0.54 |
| ▸ | MGLL | Q99685 | 4/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | MASP2 | O00187 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009097 | 0.92 | MGLL (0.50) | CMA1CTSGMGLLMASP2NPC1 | |
| SCHEMBL410155 | 0.92 | CMA1 (0.57) | CMA1CTSGMGLLACP3MASP2 | |
| SCHEMBL13009387 | 0.89 | MGLL (0.48) | CMA1CTSGMGLLMASP2CAPN1 | |
| SCHEMBL13996273 | 0.86 | CTSG (0.52) | CMA1CTSGMGLLACP3MASP2 | |
| SCHEMBL8290988 | 0.82 | MGLL (0.47) | CMA1CTSGMGLLCAPN1CTSB | |
| SCHEMBL27668978 | 0.81 | MGLL (0.67) | MGLLCAPN1CTSBNPC1RAB9A | |
| SCHEMBL14000867 | 0.81 | CTSG (0.49) | CMA1CTSGMGLLACP3MASP2 | |
| SCHEMBL8291221 | 0.80 | MGLL (0.49) | CMA1CTSGMGLLACP3MASP2 | |
| SCHEMBL10317420 | 0.79 | MGLL (0.50) | CMA1CTSGMGLLCAPN1CTSB | |
| SCHEMBL10197956 | 0.78 | MGLL (0.56) | MGLLCAPN1CTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| EP-1716160-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | EP | disclosed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176769-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885MGLL 1024/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885MGLL 1024/4885 |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885CTSG 166/4885MGLL 1025/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 36/4885MGLL 1024/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | CMA1 1/4885CTSG 166/4885MGLL 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.